Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention (Naco_Nîmes)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02273700|
Recruitment Status : Completed
First Posted : October 24, 2014
Last Update Posted : August 24, 2016
|Condition or disease||Intervention/treatment|
|Atrial Fibrillation||Drug: Rivaroxaban|
|Study Type :||Observational|
|Actual Enrollment :||5 participants|
|Official Title:||Evaluation of Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention in Patients With Atrial Fibrillation|
|Study Start Date :||November 2015|
|Actual Primary Completion Date :||January 2016|
|Actual Study Completion Date :||January 2016|
the Study Population
The study population consists of patients in the cardiology department at the Nîmes University Hospital with non-valvular atrial fibrillation and who are candidates for treatment with a direct oral anticoagulant: Rivaroxaban (Xarelto®). Patients will be selected according to criteria designed to result in a homogeneous population (associated anticoagulants, etc., see below). For this study, patients must not have had a direct oral anti-Xa (activated Factor 10) in the 6 months preceding enrollment.
Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.
Other Name: (Xarelto®)
- The percent change in plasma protein/peptide profiles after one month of treatment versus before treatment [ Time Frame: 1 month (between days 28 to 35) versus baseline (day 0) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02273700
|CHRU de Nîmes - Hôpital Universitaire Carémeau|
|Nîmes Cedex 09, France, 30029|
|Principal Investigator:||Géraldine Lavigne-Lissalde, MD||Centre Hospitalier Universitaire de Nîmes|